BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best immunology stocks to buy ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

At Stock Options Channel, our YieldBoost formula has looked up and down the BNTX options chain for the new June 2026 contracts and identified one put and one call contract of particular interest.

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Next: Get access to a new market-moving chart every day featuring a stock flashing clear technical signals. See today's pick now. BioNTech SE BNTX on Monday reported fourth-quarter per-share ...